Kala Pharmaceuticals Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | -0.1 | 0.0 | 0.0 | -0.1 | +0.1 | -0.0 | 0.00 | $-120.20 | $12,225.00 | -1.0% |
| 2019 | -0.1 | 0.0 | 0.0 | -0.1 | +0.0 | -0.1 | 0.00 | $-152.07 | $9,225.00 | -1.6% |
| 2020 | -0.1 | 0.0 | 0.0 | -0.1 | +0.0 | -0.1 | 0.00 | $-101.14 | $16,950.00 | -0.6% |
| 2021 | -0.1 | 0.0 | 0.0 | -0.1 | +0.0 | -0.1 | 0.00 | $-95.11 | $3,025.00 | -3.1% |
| 2022 | -0.1 | 0.0 | 0.0 | -0.1 | -0.0 | -0.1 | 0.00 | $-2,835.36 | $1,907.50 | -148.6% |
| 2023 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.0 | 0.00 | $-740.13 | $350.00 | -211.5% |
| 2024 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.1 | 0.00 | $-500.25 | $347.00 | -144.2% |
| 2025 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.1 | 0.00 | $-239.32 | $27.80 | -861.0% |
| 7-yr CAGR | n/m | -2.9% | -48.6% | n/m | n/a | n/m | -15.6% | n/m | -58.1% | avg -171.5% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2018 | 0.0 | -0.1 | n/m | 0.1 | 0.2 | 7 | 6 | n/m | n/m |
| 2019 | 0.0 | -0.1 | -1,438.6% | 0.1 | 0.1 | 6 | 6 | n/m | n/m |
| 2020 | 0.0 | -0.1 | -1,498.3% | 0.1 | 0.2 | 18 | 18 | n/m | n/m |
| 2021 | 0.0 | -0.1 | -964.9% | 0.1 | 0.1 | 4 | 4 | n/m | n/m |
| 2022 | 0.0 | -0.1 | -2,076.5% | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 2023 | 0.0 | -0.0 | n/m | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 2024 | 0.0 | -0.0 | n/m | 0.0 | 0.1 | 0 | -0 | n/m | n/m |
| 2025 | 0.0 | -0.0 | n/m | 0.0 | 0.0 | 0 | -0 | n/m | n/m |
| 7-yr CAGR | n/m | n/m | avg -1,494.6% | n/m | -36.0% | -64.6% | n/m | median n/m | avg n/m |
Revenue grew n/m a year and EBITDA n/m a year from FY2018 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count fell 15.6% a year through buybacks. Net debt stood at n/m EBITDA at the last fiscal year-end.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 26% in FY2018 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 28% in FY2019 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 53% in FY2020 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.